Good morning, and welcome to the Precision BioSciences investor update. At this time, all attendees are in a listen-only mode. A live question and answer session will follow the formal presentations. To our covering analysts, please use the raise hand feature to be added to the queue. As a reminder, this call is being recorded, and a replay will be made available on the company's website following the event. I will now turn the call over to Naresh Tanna, CFO of Precision BioSciences. Please go ahead.
Good morning, everyone, and welcome to the Precision BioSciences AASLD 2026 Investor Update, live from the liver meeting in Denver, Colorado. Thank you all for joining today. Next slide, please. During this morning's call, we may make forward-looking statements. I would invite you to review our 10-Q, which was published last week on November 3rd. The 10-Q includes risk factors that could cause actual results to differ from any forward-looking statements made today. Next slide, please. I am joined today by Michael Amoroso, President and Chief Executive Officer, and Dr. Cassie Gorsuch, our Chief Scientific Officer. We are also honored to be joined by two leading hepatology infectious disease experts.
Next slide, please.
Dr. Mark Sulkowski is Professor of Medicine and Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. Dr. M.F. Yuen is Chair Professor in the Division of Gastroenterology and Hepatology at the University of Hong Kong. All of today's speakers will be available during the Q&A portion. Without further ado, I will hand the call over to Michael.
Thank you, Naresh. Welcome to everybody, and welcome to our investor community. Thank you for being with us. We are very excited on the back of presenting our late-breaking oral presentation yesterday on Sunday. Today, I am joined by my esteemed colleagues. We will walk you through that data, what that data means, and what that looks like for patients and for Precision going forward. Next slide, please. Viral cure. This will be a very important concept that we discuss throughout the day, the eradication and elimination with PBGENE-HBV of cccDNA, undetectable HBV DNA off of therapy. Next slide, please. The problem for the last 50+ years in development of chronic hepatitis B is we have never been able to get at the replicating viral source, cccDNA, until now.
PBGENE-HBV is a lipid nanoparticle gene editing delivery system that targets the cccDNA, the viral source of replication and infectious particles, and eliminates that source. As you can see on your right-hand side, we have had breakthroughs through decades of drug development, but most and all drug development has truly focused on downstream RNA transcripts and proteins coming from the virus. The hope was that we would suppress these transcripts and proteins and allow the patient's immune system to eradicate the cccDNA on its own. Unfortunately, to date, that has been a long journey and an unattainable task. We hope now with the advent of a direct targeting cccDNA elimination agent like PBGENE-HBV, we can change the outcomes for patients going forward permanently. Next slide.
When we last met, the end of May at EASL, Precision and the team came out and told you phase I data, the first gene editor, the first targeting of cccDNA and elimination ever in chronic hepatitis B. We told you about 100% treatment effect in 16 patients across 38 administrations. We told you about the advent of a key blood biomarker for intervening with therapy, for knowing when to stop your nucleoside analogue. We talked about the advent of the pgRNA blood biomarker. In six patients, everyone treated with PBGENE-HBV had 100% undetectable pgRNA post-treatment. We told you we were going to watch the durability. Permanence is critical for elimination. Next, we showed you the first evidence of cccDNA direct targeting and elimination by PBGENE-HBV through the gold standard molecular biopsies, tissue of the liver, log reductions of cccDNA, not viral proteins downstream.
Most importantly, we started to characterize the safety of PBGENE-HBV in patients with chronic hepatitis B across four different dose levels, 0.2, 0.4, 0.65, and 0.8, with a focus going forward on the 0.4 and 0.65 doses. The team told you we wanted to enroll more patients with the enriched blood biomarker of pgRNA. We wanted to get more experience in the 0.4 and 0.65 dose. We must see the critical durability of over six months after PBGENE-HBV. Remember, pgRNA is the proxy for HBV DNA, the FDA endpoint off therapy. We wanted to further look at our safety characterization and profile of these two different dose levels. I am very proud of this team, and I am proud today to be able to tell you Precision has done just that.
25 patients, 59 administrations, with a go-forward plan to move success in phase I to move to phase II at a 0.4 mg/kg dose. Next slide. The data behind the late-breaking oral presentation that M.F. Yuen had presented yesterday, and a wonderful job, M.F. Thank you very much. First, reproducible liver biopsies. We showed you the first proof at EASL, and now we show you another patient at 0.4 mg/kg , the go-forward dose, with one and a half log reduction, 35-fold decrease in cccDNA at the liver. Next, the pgRNA-enriched population, those with the blood biomarker indicative of cccDNA in the liver. pgRNA, now 11 patients. Green is good, 100% undetectable. When you go undetectable with pgRNA after PBGENE-HBV treatment, patients stay undetectable. Not one patient has come back. They stay green, as you can see in the swimmer's plot. Next, the toughest-to-treat population.
Physicians asked, "How would PBGENE do when the disease burden is greatest?" The 20% of chronic hepatitis B, the early infected, HBeAg positive. This is a population with two to three logs more wild-type cccDNA in their liver. PBGENE-HBV is potent at 0.4 mg/kg , the go-forward dose, and with one dose, was able to eradicate 99% of pgRNA, starting in a patient with 5,600 copies per milliliter. After the second dose, as you can see by your purple arrow, completely undetectable, and the patient has stayed undetectable. So whether you have the blood biomarker or whether you don't, if you have lower disease or in the highest disease burden, PBGENE-HBV continues to have a treatment effect in all patients.
Heterogeneous disease, but a homogeneous impact, and is continuing to eliminate pgRNA, the HBV DNA biomarker, when on a nucleoside analog in all patients. Next, Mark, I'd love to get into a little bit, Mark Sulkowski. Dr. Sulkowski, can you please tell us a little what you think this data could mean for the field? What are you hearing amongst your peers in Denver?
Well, thanks, Michael. I'd like to just take a step back on this particular slide of the antigen-positive and think about people with hepatitis B, generally infected at birth, initially very high levels of infection. When we talk about an HBeAg positive patient, we're talking about a tremendous amount of cccDNA in the liver, and the biomarkers, as depicted here, pgRNA, is quite high. The natural history and treatment with NUCs over decades, you may see reductions in this biomarker as they shift into the antigen-negative state. I think for me, one of the most remarkable things here is that with a single dose of PBGENE, that occurred in days and weeks, not decades. I think there's been a lot of excitement at the liver meeting about advances in HBV therapeutics, and PBGENE is part of that discussion.
Thank you, Mark. Look forward to continuing our conversation today. Next, please. As discussed, today marks an important chapter for patients, for Precision BioSciences, and the team, and we want to thank all the patients and our investigators. Today, we declare success in phase I, and the company is moving forward rapidly to phase II, where we will test for cure rates off drug therapy. I am going to turn it over to Cassie to tell you the evidence behind the late-breaking oral presentation and why we have such confidence to move forward into testing cures in the phase II setting. Cassie?
Thank you, Michael, and thank you all very much for joining us this morning. It is really my pleasure and privilege to be able to share on behalf of the Precision team, our patients, and our investigators, the exciting data coming out of the ELIMINATE-B study. I am going to start with a little bit of disease background to help set the stage for this novel approach. The viral life cycle for hepatitis B is shown here. cccDNA in the liver is the full viral genome that gives rise to pgRNA, which is the precursor to HBV DNA. cccDNA makes pgRNA, makes HBV DNA, and this HBV DNA can circulate back to the liver, repopulate the cccDNA pool, and this is the viral life cycle for hepatitis B.
As a field, we have known for a long time that cccDNA is really the ideal therapeutic target, but we have never had a drug that could directly target and eliminate cccDNA. We have also agreed that cccDNA elimination in the liver is a path towards a true viral cure for hepatitis B, and cccDNA elimination, in our view, is really the only path towards a true viral cure for patients. The patients on the ELIMINATE-B study are on standard of care nucleoside analogs, and I want to point out where NUCs work. They prevent the conversion of pgRNA into HBV DNA. While patients are on NUCs, HBV DNA is suppressed and not measurable in the blood. However, the precursor to HBV DNA, pgRNA, is detectable in some patients, and pgRNA is only produced from cccDNA in the liver.
Of course, evaluating cccDNA in the liver requires biopsies, which we are excited to be able to share with you today, but is not practical for every patient in a clinical setting. However, pgRNA in circulation is a great biomarker because it is specific to cccDNA and is the precursor to HBV DNA. PBGENE-HBV is an ARCUS nuclease encoded by an mRNA and encapsulated in a lipid nanoparticle. It is delivered to the liver and targets and eliminates cccDNA. When you eliminate cccDNA, you prevent the production of downstream markers, including the biomarker pgRNA and the regulatory endpoint, the HBV DNA in blood.
The goal for this program, for PBGENE-HBV, for our approach at Precision for hepatitis B, is to eliminate cccDNA in the liver, measure that by undetectable pgRNA as the biomarker, and after a finite course of treatment, stop nucleoside analogs and look for maintenance of HBV DNA suppression. The endpoint is, as Michael mentioned, aligned with FDA guidance already of undetectable HBV DNA off treatment. Here you can see a snapshot from the guidance document from FDA indicating two potential paths for approvable endpoints. The first one you will notice is undetectable HBV DNA off treatment, irrespective of S-antigen levels. The second one is functional cure, as we are all aware of undetectable HBV DNA and S-antigen loss.
You will see as we progress to the phase II study design that we will be testing for both of these endpoints in the context of our phase II study. Now, let us jump into the ELIMINATE-B data. Starting first with patient baseline characteristics. You can see here a real-world representation of chronic hepatitis B patients. Our ELIMINATE-B study is enrolling in multiple geographies across the globe, including on three different continents, really with the goal of capturing a real-world population of hepatitis B patients. We have evaluated doses between 0.2 and 0.8 mg /kg . As Michael mentioned, we now have 59 administrations and 25 patients across these four dose levels. I am excited today to share with you the data that demonstrates the safety and efficacy of 0.4 mg/ kg as our go-forward dose for our phase II study.
As you can see, over half of our clinical experience is at this dose level, so 13 participants, 30 administrations have been dosed at 0.4. Starting first with that primary biomarker, pgRNA. It is the biomarker for cccDNA elimination in the liver. Since our EASL update, where we had with undetectable pgRNA after treatment with PBGENE, we have now doubled up the number of participants on the ELIMINATE-B study with detectable pgRNA at baseline. The way to read this graph is that the gray part of the bar indicates that pgRNA is detectable in the blood. When the bar goes green is when a participant achieved undetectable pgRNA in the blood, and the black diamonds are doses of PBGENE.
What you can see is 11 of 12 patients now have undetectable pgRNA after treatment, with that remaining patient 95% reduced from baseline and continuing to decline as of the data cutoff. We expect that this patient is on their way to undetectable, like everyone else in this group. I also want to point out that all 6 of these initial patients, this was the EASL cohort, all of these patients we have continued to follow with approximately monthly blood draws, continuing evaluation, and all of these patients have remained pgRNA undetectable in the blood, demonstrating the durability of this effect. When you go green, you stay green. Elimination of cccDNA in the liver leads to undetectable levels of pgRNA in the blood, and that effect is durable.
The other thing I want to point out in this pgRNA data is if we subset the patients that have been treated at the lowest dose to achieve pgRNA loss, the 0.4 mg /kg , all of them have achieved undetectable pgRNA. This is six of the 12 patients that we had on the previous slide, and this really demonstrates that 0.4 mg /kg consistently drives cccDNA elimination, resulting in pgRNA loss in the blood. Very consistent effect. Importantly, one of these patients is our first e-antigen-positive patient that we dosed on study. Why do we care about e-antigen-positive patients? As Mark nicely illustrated earlier, e-antigen-positive patients are a very important population because they have two to three log higher cccDNA burden in their liver, more infected hepatocytes, more pgRNA. This is historically a difficult-to-treat patient population. You can see that visually depicted here.
E-antigen positives, more cccDNA, more infected hepatocytes in the liver, more pgRNA in the blood compared to e-antigen-negative patients. We went into this population for a few reasons. One, we wanted to understand the potential dose effect. I showed you that in the e-antigen-negative patients, we achieved pgRNA loss at 0.4, 0.65, and 0.8. We thought in this population with more cccDNA in the liver that we may be able to differentiate doses with a higher dynamic range. The second is, of course, this is an important population because historically they have been harder to treat, less positive outcomes with existing therapies. We were really pleased to see that in that first e-antigen-positive patient that we dosed on study, this patient was dosed at 0.4 mg /kg .
You can see after their first dose, indicated in the pink dotted line to the left, a very rapid and dramatic reduction in pgRNA levels, all the way down to undetectable right around the time of their second dose. This patient is really notable because this patient started with 3.7 log or almost 6,000 copies of pgRNA in the blood, two to three logs higher than what we see in a typical e-antigen negative patient. This was very convincing data for us that 0.4 mg /kg can drive potent biodistribution and potent cccDNA effect in the liver. Now I'd like to spend a few moments talking about liver biopsy data. Of course, liver biopsies are optional in the ELIMINATE-B study, so not every participant consents to optional liver biopsies.
I do have two patients now at our 0.4 mg/kg go-forward dose level to share liver biopsy data with you on. Starting first with patient five. This patient had a baseline biopsy prior to any of their doses of PBGENE, and then a second biopsy after dose two. What we can look at in these liver biopsies is the fraction of cccDNA transcripts in these two longitudinal biopsies. What you can see is in that second biopsy, a 10-fold or one log decrease in the amount of cccDNA transcripts compared to that first biopsy, demonstrating mechanism of action, PBGENE-HBV targets and eliminates cccDNA, and does so very potently at 0.4. We have reproduced this biopsy data now in a second patient six.
This patient had their first liver biopsy after their third dose, as well as a follow-on biopsy after an additional dose. Here we can see a 35-fold or 1.5 log decrease in cccDNA-derived transcripts. So reproducible, consistent effect of cccDNA elimination in the liver at 0.4 mg/kg , and importantly, proof of mechanism for PBGENE. I will spend a few moments talking about S-antigen. S-antigen is an important secondary biomarker for PBGENE-HBV. Let me explain why we think of it as a secondary biomarker. I told you before, pgRNA is specific to cccDNA. It only comes from cccDNA. S-antigen can come from both cccDNA, the replication-competent source, as well as integrated HBV DNA, which is not replication-competent. When PBGENE-HBV eliminates cccDNA, we expect to see an associated S-antigen decline, but potentially not an entire loss of S-antigen.
It is secondary to pgRNA because it is not specific to cccDNA. In patients that have been dosed on study, you can see a very consistent S-antigen effect after treatment with PBGENE. Here you are looking at a maximal S-antigen decline from baseline across all evaluable patients, 24 of the patients. What I will point out is that substantial S-antigen declines have been observed independent of baseline characteristics, such as pgRNA positive at baseline or baseline S-antigen levels. So very consistent activity of PBGENE-HBV across all of these participants. The other notable piece of data here is when we look at the effect of dose, we compare 0.4, 0.65, and 0.8. All of these doses gave us durable S-antigen declines, as well as pgRNA loss, as I showed you on the swimmer plot.
Consistent with what we saw on the swimmer plot, 0.4 mg/kg is sufficient to drive maximal S-antigen declines as well. So really no added benefit in doses above 0.4 mg/kg , demonstrating 0.4 is a sufficient maximally efficacious dose. I would like to spend a few minutes talking about the safety profile for PBGENE-HBV. I am going to share with you on the safety data 59 administrations, 25 evaluable patients. Of course, as a phase I study, safety was the primary endpoint, and no dose-limiting toxicities have been observed. The most common adverse events that we see in this program are consistent with known lipid nanoparticle effects, so infusion-related reactions that occur on the day of dosing and typically resolve within a few hours. Also consistent with known LNP effects, we see transient reversible transaminase lab abnormalities after the infusion.
It is important to note that all of these transaminase lab abnormalities have been asymptomatic. We have seen no changes in bilirubin associated with any of those lab abnormalities, and of course, no cases of Hy's Law. Today, I will focus on safety at the 0.4 and 0.65 mg/kg dose levels, as those were the doses that we had continued exploring as of the middle of the year. We previously shared data on safety at other dose levels and had not continued dosing outside of 0.4 and 0.65. So here you are looking at the number of patients with adverse events that were either related to PBGENE-HBV or potentially related to PBGENE. One important piece of context is towards the beginning of this year, we noticed that with repeat infusions, there was an inflammatory response associated with the lipid nanoparticle.
We made some modifications to our infusion protocol to help address that inflammatory response. Those included extending the infusion duration from two hours to five hours, increasing the amount of steroids that patients were receiving on the day of dosing from 10 mg - 20 mg dexamethasone split between two doses, as well as a prophylactic saline infusion. So whenever you see on the slide current infusion protocol, those are the changes that we made and will be implemented into our current infusion protocol. Now, at the 0.4 mg/kg , eight of the 13 patients have been dosed with that current protocol, and they are indicated in the purple box to the top right. What you can see is that this protocol continues to be effective for ameliorating grade three hypotension at the 0.4 mg/kg dose level.
No observed at the go-forward dose with the current infusion protocol. There was one delayed transaminase lab abnormality in one participant on that third administration, and it is detailed in the second bullet on the slide. So an overall moderate increase with ALT at 306 and AST at 278. No intervention was required for this transaminase lab abnormality, no changes in bilirubin, no cases of Hy's Law. Now, one thing I want to point out, in the context of our ELIMINATE-B phase I study, we have been using the DAIDS AE grading system. It is very common in the context of lipid nanoparticles to utilize a different grading system called CTCAE. Now, that grading system is used for lipid nanoparticles because it includes a grading scale for infusion-related reactions, which, as I told you, are a common side effect with LNPs.
We will plan to use the CTCAE grading system for our phase II study. So we have evaluated the context of the safety events in our phase I study under CTCAE, and that is shown here. What you can see is that none of the hypotension that had been observed on study under the CTCAE guidance is considered grade 3. This indicates that while these were hypotensive events that were managed with saline under DAIDS, the saline reactive use illustrates it as a grade three hypotensive event. That is not the case for the CTCAE grading scale. So overall, the 0.4 mg /kg with the current infusion protocol demonstrates a favorable safety profile for our phase II study. In summary, we have generated a robust safety and efficacy dataset, particularly at the 0.4 mg/kg dose level that we are very excited about.
I would like to invite Dr. M.F. Yuen, our investigator at our Hong Kong site, to please provide his perspective on the data and the meaningfulness of this dataset.
Hey, Cassie. I would like to thank the Precision BioSciences team for the dedication of these studies and also our investigators. We can now say with high confidence that PBGENE-HBV directly attacks cccDNA, the root cause of the hepatitis B infection. The evidence is compelling. Liver biopsies show a deep reduction in cccDNA transcripts, and we observed a 100% reduction in the pregenomic RNA in the e-antigen-positive patients. This loss of pg pregenomic RNA has been prolonged and also sustained, which further strengthens our conviction that the effect is real and doable. Based on these results, I am very confident and eager to advance the additional studies already planned. PBGENE-HBV has the potential to transform the treatment paradigm for chronic hepatitis B infection and to meaningfully improve patients' lives.
Thank you, Dr. Yuen, and thank you for presenting the data for the late breaker abstract that we submitted for the liver meeting. Really exciting to see this data on the main stage at the liver meeting, and thank you for your continued support for the program. With that, I would like to talk about what is next for PBGENE. Here, we are going to share the details of our phase II study design. Here you can see that we plan to test PBGENE-HBV in our phase II study in two contexts. One as a monotherapy, and hopefully, on the basis of the data that we just shared with you can see why we are so excited about the potential of a finite course of treatment of PBGENE to achieve a monotherapy viral cure for patients, measured by undetectable HBV DNA off therapy.
In addition to this viral cure monotherapy arm, we are also including a sequential treatment regimen with PBGENE-HBV treatment first, followed by an antisense oligonucleotide treatment. In this arm of the study, we will be looking to stop NUCs and measure for functional cure, defined by undetectable HBV DNA and S-antigen off treatment. Let us talk a little bit more about the rationale for that second arm. When you look at the state of chronic hepatitis B treatment today, we mentioned functional cure, undetectable S-antigen, and HBV DNA off treatment. With the recent approval of Hibsago from GSK, or bepirovirsen, you can see the functional cure rate demonstrated 19% in the phase III studies. On the viral cure side, we think of this as a true viral cure with cccDNA elimination in the liver, which, based on this novel mechanism, first-time cccDNA elimination has not been demonstrated before.
Really, we think of PBGENE-HBV as the potential to enable the better viral cure for PBGENE for hepatitis B patients. The rationale for the potential combination, I would like to spend a few minutes thinking about how we think about PBGENE-HBV prior to that ASO arm. Next slide, please. When you look at the phase III Oh, we are jumping around a little bit. When you look at the phase III bepirovirsen data, you can see that bepirovirsen was most effective in patients with lower viral burden in the liver. The antigen-positive patients that were enrolled in the phase III study achieved only an 8% functional cure rate. If you look at the S-antigen stratification from the paper, you can see that the lower the S-antigen, the more effective bepirovirsen was, indicating lower viral burden can correlate with improved functional cure rates.
We have demonstrated the potential synergy of PBGENE-HBV plus bepirovirsen in a transgenic mouse model. We used this transgenic mouse model to test the potential for PBGENE-HBV treatment first, followed by an antisense oligonucleotide. The way that we did this is we treated mice with a finite course of an ASO alone, as shown in orange bars, as well as mice treated with PBGENE-HBV first, followed by that antisense oligonucleotide for a period of time. We followed these mice for four weeks after that treatment and measured HBV DNA and S-antigen, the two endpoints for functional cure. What you can see is in the combination arm, when PBGENE-HBV preceded the ASO, we have a deeper and more durable decline in both HBV DNA and S-antigen, demonstrating the synergy of combining these two modalities. Here's a more detailed view at how the phase II study design works.
Patients will come in on nucleoside analogs. In both arms, they will first receive three doses of PBGENE-HBV at 0.4 mg/kg on a Q8 week schedule. In the monotherapy arm, we will look for undetectable pgRNA, durable undetectable pgRNA, as the guiding principle for stopping nucleoside analogs. Of course, we'll stop NUCs and look for undetectable HBV DNA off therapy. In the combination arm, after the three doses of PBGENE-HBV, patients will receive an antisense oligonucleotide, look for undetectable HBV pgRNA, as well as S-antigen, with the goal of measuring functional cure off therapy. As you can see, really robust data now for the ELIMINATE-B study. Very exciting time as we progress this program to our phase II study. I'd also like to spend a few minutes talking about our second clinical program now, our FUNCTION-DMD study.
This study is now testing PBGENE-DMD for Duchenne muscular dystrophy. The approach for PBGENE-DMD is demonstrated here. It utilizes the same ARCUS technology as our PBGENE-HBV program, but in this case, utilizes an AAV for delivery of those ARCUS nucleases to muscle. A single AAV encoding two ARCUS nucleases. Those ARCUS nucleases are designed to cut and excise exons 45 to 55 of the dystrophin gene. When this region of the dystrophin gene is removed, it restores the reading frame, allowing for the production of a functional dystrophin protein. This approach is applicable to up to 60% of patients with DMD because the majority of DMD patients have pathogenic mutations in this hotspot region of the dystrophin gene. We've demonstrated a robust preclinical data package showing that PBGENE-DMD can restore dystrophin protein across important muscle groups like the heart and the calf.
What we know from natural history data is that as little of about 5% of this near full-length functional dystrophin protein is sufficient to correlate with therapeutic benefit in DMD patients. Here on the right, you can see data from a preclinical humanized DMD mouse model showing the ability of PBGENE-DMD to well exceed that 5% dystrophin expression threshold, achieving up to nearly 15% dystrophin in the heart and about 20%-25% in the calf. Importantly, as you can see here, that dystrophin protein grows over time from three months to nine months on the basis of editing satellite stem cells and expressing a very stable, near full-length dystrophin protein. PBGENE-DMD is currently being tested in the phase I/II FUNCTION-DMD study, and the design is illustrated here. We are enrolling boys with mutations in that hotspot region, ages two to seven.
I'm excited to share with you that we've successfully dosed patient one on this study, and I'll share a safety update on patient one here in just a moment. We've also enrolled patient number two, and we currently have patient number three in screening, which puts us on track for completing our goal for the program of enrolling this part one safety cohort of the FUNCTION-DMD study by the end of the year. I'm very happy to be able to share that PBGENE-DMD was well tolerated in patient one, who was successfully dosed at Arkansas Children's Hospital in August of 2026. No serious adverse events and no adverse events of special interest have been observed in this participant. This is notable because it's an AAV therapy in Duchenne muscular dystrophy kids, where challenges with AAV tolerability have been observed in the context of other studies.
Importantly, no evidence of TMA, myocarditis, or acute liver injury in this first initial participant. We reviewed this data with our independent DSMB, and they identified no safety concerns, as well as endorsed the decision to continue dosing patients number two and three to complete part one of this study. As I mentioned, we are on track to meet the goal of three patients enrolled in this study by the end of the year, and we look forward to additional safety data, as well as biopsy data. As a reminder, we are taking muscle biopsies from these participants at baseline, 12 weeks, and 12 months post-dosing. We will look to be able to share that biopsy data, as well as additional safety data in 2027, and continue to part two of this study. With that, I'd like to hand it back over to Michael Amoroso.
Thank you, Cassie. Thank you, M.F., and thank you, Mark, for the wonderful presentation. Next slide, please. You may have recently seen that Precision was able to extend their financing runway into Q4 2029, and very importantly, through the key late-stage clinical inflection points of a global phase II PBGENE-HBV study that we're calling ELIMINATE-B2. That, again, will test PBGENE for viral cure as a monotherapy, and it will also test in the combination with bepirovirsen in combination for functional cure as well as for viral cure. The funding also extends our ability to continue to operate on program two. As we say at Precision, we love both of our children, and we're very excited for patients with DMD of what this could possibly mean to take back near full-length dystrophin.
Cassie showed you that phase I,II will complete in 2027, but we are now fully funded to take our pivotal through 2028 and 2029. So very meaningful clinical inflection points for patients first, for shareholders next. Global phase II, as well as a full pivotal for DMD. Precision brought in $125 million in proceeds. We did a raise here in the last couple of days, announced last Thursday. Again, we thank our new partners as well as pre-existing partners, as we couldn't do the science without you. So thank you so much. Again, patients is our key focus here. Next slide, please. How these inflection points layer for the next 12 months, critical next 12 months for Precision. If you look first at the global phase II for PBGENE-HBV, our ELIMINATE-B2 trial, we've already had a team out in Asia. This will be a global trial.
We've had a team out in Asia onboarding sites, as well as in the U.S. and Europe. We will be doing global accrual of an open label in the first half of next year, and what that will yield is some results already from the monotherapy and the combo arm that we'll be able to update into the second half of next year, some initial data there. Study will complete in 2028. However, in an open-label nature, Precision will be able to communicate at key data points along the way, starting in the second half of next year. In addition and in parallel, Cassie told you about the very, very critical data coming out of DMD. First, we're on track to finish our part one safety data this year with the data coming out in Q1 of next.
That will unlock our ability to treat patients safely in DMD concurrently, and our three-month first look at biopsy data, dystrophin expression from a near full-length dystrophin gene, not a synthetic gene, taking back the body's native dystrophin, will be in that April/May timeframe, Q2, as well as the base case for dystrophin expression and functional improvement. It's not about dystrophin without functional improvement, will be in Q4 of 2027. So you see a data-rich catalyst year ahead of us for the next four quarters, enabled by our partners, our current and our new investment partners, and we thank them very much. Next slide. Now I want to open up to Q&A, and we're going to spend time to get to all of your questions. We are excited about the data. We know we've already seen some questions coming in of new paradigm.
I'll preface some of the things that have come in on the line. I think Cassie showed a slide that's so important on slide 13, if you guys can go there as I open up to Q&A. If someone could cue slide 13. I'm going to remind everybody, we've known cccDNA is the problem and the only source of replicating virus. That has to be the target to eliminate, not suppress, not silence, extinguish this virus, to stop viral integrations, to stop the ability for patients to progress, unfortunately, to hepatocellular carcinoma. To date, hepatocellular carcinoma rates are still going up. The target is cccDNA. The biomarker, while Cassie told you, while on the nucleoside analog, a direct measure of cccDNA in the liver is pgRNA in the blood. Not all patients have this biomarker. In fact, it's the patients that have more disease, the tougher to treat.
But remember what pgRNA is. It is not the FDA endpoint. It is the surrogate proxy for HBV DNA, which is the endpoint by the FDA when you're on the NUC. One molecule of pgRNA is necessary in order to make one molecule of HBV DNA. So pgRNA is so important while you're still on the NUC to have them undetectable, stay durably undetectable, stop the NUC, and then the FDA endpoint, of course, is off-therapy HBV DNA in the blood. I just saw some of the questions coming in already. I wanted to remind everybody, because I realize most therapy has targeted suppression of downstream biomarkers, ones we also look at, such as S-antigen. These are nonspecific to cccDNA. This math equation, as we call it, is the key for PBGENE-HBV. With that, I'm going to open up to Q&A and the questions coming in. Thank you.
Thank you, Michael, and to all of our speakers. At this time, we will be conducting a live Q&A session. To our covering analysts, please use the raise hand feature to be added to the queue. Please hold for a brief moment while we pull for questions. The first question comes from Maury Raycroft at Jefferies. Please go ahead, Maury.
Maury.
Hi.
Maury, we can hear you.
Hi, can you hear me?
We can hear you now, Maury. Yep.
Okay, great. Congrats on the update and showing the data at AASLD. I am wondering for the phase I, will you explore stopping NUCs for any of these patients? For the phase II viral cure plan, what more can you say about the criteria that you are going to use to stop NUCs in phase II?
Yeah. I will take the first part, and then I will open it up to Cassie and then our key physicians who are going to help us execute the trial on the execution of phase II. Maury, phase I, remember, we have got about 25 patients now, team. That is about half of them had more disease in the liver, right? Including the pgRNA enriched E positive we just showed you. Those are the folks that have pgRNA in the blood, Maury. You are right, we did just pass in our first half the EASL cohort, the vital six month and a day off therapy time point to know that ethically and safely it would be potential, an ability to stop NUCs in the phase I.
The one thing we wanted to make sure the community heard, it is really important to test cure rates at one single dose, really with some stats and power, looking at a treatment effect. We all get excited to stop in onesie, twosies, Maury, and we will look to do that with the phase I investigators. We do not have a set plan just yet. The second half of the swimmer's plot will get past the six-month mark toward the end of Q1 of 2027. Remember, that was all different dose levels. We will work with each investigator. I think there is an excitement to stop the patients that did not have pgRNA in the blood, because you could argue maybe those are the easiest to eliminate. They have less cccDNA in the liver, therefore not the pgRNA blood biomarker.
That is why Cassie showed you S-antigen as a secondary marker, Maury, because that shows a treatment effect in all 24, right? About half the population has the pgRNA enriched. Everyone has gone undetectable. One patient is just about there, almost everybody, 95%. We think they will get there on the next blood marker. That was the data cutoff. When we get to the end of Q1 next year, everyone will be past that important six months and a day off therapy, and I think we will, with the investigators, look to stop NUCs in those patients. Remember, there are very different doses. Some of those patients had doses at 0.8, 0.65. We have got to take that data with a grain of salt. I am as anxious as you to see it. We have not stopped anybody yet.
But what was most critical is we had to pick a safe go-forward dose, 0.4, and we got to put it in a powered environment where we're really looking at a treatment size effect. We will do both of those things in parallel at some point, but we haven't promised exactly when that will be. I think it's important for you to think, Maury, six months off PBGENE, continue to stay undetectable, happens at the end of Q1 2027, and I think we can look case by case with the investigators. With that, I'll ask M.F. and Mark to comment on anything around the phase I if they want, when the question comes up. I'm going to take the second half of the question.
I'll start with Cassie on the phase II design and kind of what we're thinking for the stop NUC criteria, and I'll ask M.F. and Mark to please weigh in. Please.
Thank you, Michael. This is a very good question. For the phase I study, we originally didn't have a plan to stop patients' NUCs, even though they have a pgRNA undetectability, because the phase I study was designed to look at the safety and also the dose, efficacy dose of PBGENE-HBV. But then, with the data evolving, we actually saw so many patients with pgRNA undetectability, and we are now at the phase where we are going to discuss with Precision BioSciences individually for our patients whether it will be good to stop the nucleoside analogs. But this will be designed very soon, and up to all the patients' discretion and also the investigator's discretion whether we would stop NUCs for patients, as Michael already said, at least six months after the last dose with persistent pgRNA undetectability.
Thank you, M.F. Yeah, Maury, I just caution the investor community. Again, we haven't stopped yet, guys. I'm not hedging in any way. We want to look at a treatment effect at a dose. We will do what's right for each patient, no doubt about it. We think they definitely qualify. You're seeing 100% treatment effect. But whether we go six for six, three for six, or zero for six, I think you got to caution yourself to think about a treatment effect with stats behind it. Testing cures is a phase II setting activity, and that's what we're moving feverishly to do now. Like I said, Maury, you're going to have open-label data rolling out the second half of next year. Cassie, do you want to maybe speak about both arms in the phase II?
Mark, I know you guys have been so critical in designing it, and what the thought process is in where you would stop NUCs in those arms.
Sure, I can start, and then I will ask Dr. Sulkowski to weigh in as well, provide his thoughts. pgRNA really is our guiding biomarker here for cccDNA elimination, because we know that the two are linked, that cccDNA in the liver correlates with pgRNA levels in the blood. When you see that pgRNA loss and that durable loss, that indicates that PBGENE-HBV has dramatically eliminated the cccDNA pool in the liver. We know from published literature that pgRNA levels in the blood are a positive predictor for successfully stopping NUCs. That has been demonstrated across a number of studies now. In that viral cure arm, that will be a guiding principle, looking for pgRNA undetectable, durably undetectable in patients to consider stopping NUCs.
As we talked about on S-antigen, we do expect to see durable S-antigen declines in participants indicative of treatment effect when you eliminate cccDNA. Whatever S was coming from cccDNA also gets eliminated. A durable, stable decline in S-antigen is also indicative of PBGENE-HBV effect in the liver. Those are really the indicators that we will be looking for patients to consider stopping NUCs.
Got it. That is all really helpful. Maybe one other question just on the phase II, wanted to clarify. Will all of those patients have elevated pgRNA at baseline? If they do not, can you talk more about how you are going to assess efficacy in the patients who do not have the elevated pgRNA? Could those patients get enriched in the functional cure arm?
Cassie, why don't you start with that, and Mark, why don't you weigh in a little bit? Maybe you could take through kind of the variation of the two types of patients you see in the E negative group with and without the biomarker.
Maybe we can help a little bit how you would do that. But the short answer, Maury , is we take all comers, the same way we did in our phase I. PBGENE works regardless of how large or small your disease burden is. You're just asking a really good question about how do you make that intervention decision to stop the NUC is slightly different depending on the biomarker they have. Cassie, maybe you could walk through that, and Mark, please give some color.
Sure. Yes, just to be very clear, Maury , we will accept patients who have detectable pgRNA at baseline and those who have undetectable pgRNA at baseline. I want to point back to the biopsy data that we've shared. That patient five had undetectable pgRNA at baseline coming into the study, and we can still see through liver biopsy a potent effect of cccDNA elimination, suggesting that we have likely improved that participant's chances of successfully stopping NUCs because of the removal of the cccDNA pool in the liver. Now, I mentioned earlier that S-antigen is an important secondary biomarker. This is where S-antigen can be really valuable. We do see sustained reductions in S-antigen across participants at 0.4 and higher dose levels.
We know that there is treatment effect based on the biopsy data as well as the S-antigen data, even when pgRNA is undetectable. As Michael mentioned earlier, those patients who come in with undetectable pgRNA are patients who may actually be in a position already, better position to stop NUCs. We think PBGENE-HBV further improves their success rate. We will bear that out in the phase II data, of course. But we know pgRNA in the blood is reflective of cccDNA levels in the liver. So those patients likely have lower cccDNA levels, fewer infected hepatocytes, but can still benefit from treatment with PBGENE. Mark, if you could please provide your thoughts.
Yeah. Well, thanks, Cassie. The way I think about this is you're trying to eliminate hepatitis B in the liver. cccDNA is hepatitis B in the liver, and it's a continuum. HBeAg positive, there's a very large number of hepatocytes harboring transcriptionally active cccDNA. As you move along a continuum to HBeAg negative, you've got those with pgRNA positive, they have more cccDNA that's being actively transcribed. Then you move again to HBeAg negative with a negative pgRNA, they have less. In a sense, if you can get someone to go from pgRNA positive to negative, you've addressed the harder-to-treat population, and we are addressing cccDNA that's still in those pgRNA negatives at that safe and effective dose of 0.4.
Got it. All helpful. Thanks for taking my questions.
Thank you, Maury .
Thank you for the questions, Maury . The next question comes from Moritz Reiterer at Guggenheim.
Hi, thanks so much for taking my question. This is Moritz on for Debjit. First of all, congrats on the great updates on both of your programs.
Thank you.
I have a couple of questions on the HBV side. Firstly, just perhaps a little bit more color around the meaning of undetectable pgRNA. What's the lower detection limit of that assay? Secondly, when it comes to your amended infusion protocol, you've not seen any grade 3 events at 0.4 mg/ kg anymore. Do you believe you've fully addressed this issue? Are you taking this exact infusion protocol into phase II? Thanks.
Yeah, I'll start with the second half, and I'm going to go to Cassie in a minute. First and foremost, we feel really good about the predict It's been two years, guys. We feel really good about the predictability, the ability to manage and really understand deeply, because of people like M.F., who's our biggest enroller, of what repeat LNP administrations really mean. Guys, this is the first time the world has really had representative doses of mRNA being repeat dosed for cumulative editing and elimination. Okay? What we learned here along the way was, you can have on your subsequent doses at higher dose levels, Cassie talked about that inflammatory response. That's during the day of the infusion. You just want to make sure you don't have big transient drops in blood pressure. We really did figure out what that looks like.
This is a known thing with LNPs, where that first hour and the timing and the rate in which you infuse matters. So elongating that time, taking the day of infusion from the 10 mg of dex to 20, and then pushing saline before. I think Cassie showed you, DAIDS doesn't have a criteria for infusion-related reaction, like a hypotensive event. So that's when, if you push saline, that was counted as a grade 3 event because it counts as an intervention. If you look at CT, and we're not rescoring anything, guys. We're just trying to give you a flavor going forward. If you look at CTCAE, that really is an LNP across disease states. You'll see there was nothing higher than grade 2. The intervention of saline unplanned would just allow somebody that's sitting in the hospital, that counts under the DAIDS criteria.
I think we feel really good that we understood the cytokine mechanism of hypertension, hypotension, and that we really do have a formula going forward where we're not seeing it anymore, as well as we feel really good about liver health. I mean, we've never tipped bilirubin once in this trial, haven't ever had a synthetic liver function issue. So, I think we really feel good about our characterization of the safety profile, our understanding how to mitigate, how to dose, and to go forward. With that, I'll ask Cassie to speak to the assay we use. And Cassie, if we could talk about specificity and sensitivity, because I know this question comes up a lot, but it is the best gold standard for pgRNA assay out there. Cassie?
Sure. We are using the Roche pgRNA assay for measuring blood pgRNA levels, and we selected that assay for a couple reasons. One, it has, based on the design of the assay, it's very specific for cccDNA-derived transcripts. We know that using that three prime polyadenylation signal, that those transcripts can only come from cccDNA, which is really our goal in this assay, is to monitor the cccDNA pool in the liver using this blood biomarker. So, that was really essential as we evaluated different RNA assays. To the question around the limit of detection, so I want to first say limit of quantitation for this method is 10 copies per mL. The limit of detection, which is what we're using to categorize patients as positive or negative, is five copies per mL. So, it's a very sensitive method.
One of the, as far as I know, the most sensitive method that is there in the commercial setting for pgRNA or HBV RNA methods. So, very robust method, and that specificity and sensitivity, both of those components are important for this method.
Cassie, could you just speak for a moment about, we think of all the assays we looked at, some of them can pick up RNA transcripts that are not pgRNA, and why we thought Roche was really specific to just pgRNA?
Yeah, I think just reiterating the use of the assay, the way that the Roche assay is designed, it picks up a polyadenylation signal that's only present in cccDNA. Other methods use different regions of viral transcripts for detection that may not have that same specificity as we see with that Roche assay. So, that selectivity of cccDNA-specific transcripts was essential in selection of this method.
Thanks, Cassie. Moritz?
Thanks. That's all from my end. Thank you so much.
Thank you.
Thank you, Moritz.
The next question comes from Luis Santos at H.C. Wainwright.
Sure.
Hi, good morning. This is Luis and for Patrick, congratulations on the progress and for taking our questions. I am thinking about the groundbreaking data on the first patient who was HBeAg positive. I was wondering if there is anything we can learn about the characteristics, the baseline characteristics of that patient to inform how the phase II can be designed. Also, along that line for choosing the enrollment of patients for phase II, can you tell us how you are thinking about which patients should be eligible for bepirovirsen and when? Thank you.
Mark and M.F., I am going to go to you both, please, if you could. If you could talk maybe about the significance of the E positive. Mark, maybe you could give a little color of the swimmer's plot when they are E negative, maybe what the copies are around the range of pgRNA versus the E positive, and maybe the confidence that this gives you to look at all comers here in the phase II. Mark and M.F., I will ask you guys to comment on that, please.
Sure, Michael. I'll start off with that. As I've talked about, the E antigen positive patients simply have more cccDNA that's being actively transcribed, that's reflected in the blood by levels that are higher of pgRNA. So, that individual was near 6,000. When we look at the antigen negative state, there's less actively transcribed targets or cccDNA, and the pgRNA levels are lower. So, in terms of trying to find the right dose, which is really the critical part of phase I study, we can look at a number of markers in the E antigen negative people, both the blood markers of pgRNA as well as the liver biopsies, that provided great confidence that the 0.4 mg was effective at eliminating cccDNA.
When you take it to a population with a much higher level of cccDNA and pgRNA, and that same 0.4 mg/kg dose in a single dose produces that dramatic decline, it's confidence in that dose level that's having a biologically relevant effect on ccc. I think it's a critically important population because of the fact they've got more replication.
Email with the line by line. Thank you. Mark, M.F., is there anything you would add about, as we think about phase II, enrolling those lower, higher disease burden? We've obviously seen therapies work different with lower and higher disease burden. Your confidence on the totality of this data to really look at all comers, please.
Thank you. In fact, that particular patient we presented was recruited in my center. Why we did that is because we really want to know this, I mean, PBGENE-HBV would work in patients with high viral activities, and it seems to be the case. For your information, we know that E positive patients is really difficult to treat. Back in the day on nucleoside analogs, we know that even you give nucleoside analogs, very potent nucleoside analogs, we can't achieve 100% of DNA, I mean, negativity in E positive patients. It means that, I mean, using, in this case, we used, I mean, the PBGENE-HBV, we didn't see any difference between high, I mean, patient with high viral activities and patient with no viral activities.
It tell us more that regardless of what activities level you are having in that patients, we can still use this, I mean, PBGENE-HBV, to treat the patients. For coming studies, we are open for all patients, E positive and E negative. This is exactly the reason why we are so confident and we want to, I mean, recruit both patients to this particular trial. For your information, the disease of hepatitis B, the outcome of hepatitis B really depends on how long you have been under a very high viremic state. For E positive patients, I would say, if the drug is effective, then you can treat them at the early phase, and that will be more rewarding, relatively, I mean, comparatively rewarding for patients with E negative.
But then we have a lot of populations having E negative phase and E negative disease. This study is clever in the design that we cover all the leads for our patients. That's why we are very excited to see that this study, I mean, that's not just for E positive or just for E negative.
Yeah. Thank you, M.F. Thank you, Mark. Luis, I'll give a little more color here on the phase II design, which we're rapidly enrolling and literally designing as we go. But we need to get patients to test cure rates, viral cure rates, right? When I say that, we mean HBV DNA, the gold standard, HBV DNA undetectable, regardless of other biomarkers. In the monotherapy arm, we'll be taking all comers. Just like in our phase I, there was no cap on S-antigen levels, pgRNA levels, E positives, E negatives, even people that didn't have the biomarker. So you'll have a finite course of therapy, and I think here you can expect to see E negatives and E positives. We'll be able to stratify. Remember, team, this is an open-label phase II-A.
This will inform, very important, what we do in later stage trials for pivotal approvals and/or confirmatory approvals. The reality here is you'll be looking at all comers with a finite course of PBGENE that will include E negatives and E positives. I think, Luis, to your question, on the bepirovirsen arm, you're really testing, does an RNA transcript as an ASO, does an RNA transcript kind of binder suppress it? Does that help if there is a cell or a percent or a half a percent left of cccDNA? Can that bind any of those RNA transcripts left behind from the cccDNA and take the viral cure rate higher? Similarly, when PBGENE-HBV eradicates and eliminates all cccDNA, the pgRNA, the S source from that, does that allow bepirovirsen to really focus on some of the integrants a little more in the cells?
Remember, a lot of the bepirovirsen patients didn't stop their NUCs, and they ended up at S level below 100. If we're cutting the disease burden and lowering the disease burden, Luis, at inception, before you start, we think that makes the hurdle of the ASO lower. Frankly, we know that there's an immune component, as we've seen from the data, and we think eradicating and suppressing downstream viral markers like S, but also most importantly, eliminating the actual virus, cccDNA. What will the 1+1=3 or 33 effect be of PBGENE followed by bepirovirsen? In the combo arm, you're going to see an enrolled population very similar to B-Well 1 and 2. You can look at the combo therapy and how it compares to the monotherapy. Hopefully that gives you more color of each arm.
That was very helpful. I was wondering if I could follow up on that.
Sure.
I don't know if you disclosed this, but if the patients on monotherapy bounce back, how long do you have to wait before you give them bepirovirsen?
Yeah. Again, this is a pre-specified design. This has nothing to do with bouncing back, Luis. You get your PBGENE for a finite course, and after your third administration, you will start and dose bepirovirsen the same way B-Well 1 and 2 did. But you're going to start with a much lower hurdle of virus. Where bepirovirsen performed best, if you could take me to the slide that shows the B-Well 1 and 2 data. I'm going to get you a slide number in a minute, operator.
Slide 63.
63, please. Slide 63, if you would. What you will see here, Luis, when the slide comes up, the E positive we know has the most burden of disease. We use the less than 1,000. Oh, I am looking for the slide with the E positive and E negatives. Either way, the patients in the B-Well 1 and 2 trial who did best were those who were not the E positive with the greatest burden of disease. They were the people with S-antigen with less than 1,000, indicative of a lower burden of disease. Luis, there is no waiting for a relapse. You are not stopping the NUC in the combo arm until you give three administrations of PBGENE, lower the viral burden, then you treat with six months of bepirovirsen, just like B-Well, and then you will stop your NUC. This was the slide I was referring to.
Thank you, operator. Slide 37. You will see that the bepirovirsen worked best in patients with the lower viral load at inception. We believe that at a minimum, we know PBGENE is cutting out cccDNA, the viral load, the viral load that matters, the replicating viral load, more than 99% in confirmed biopsies. That is why we are so excited. For decades, we have suppressed, we have silenced downstream proteins, S of the virus, RNA transcripts of the virus, which is the DNA level, but we have never extinguished or eliminated. Now we give these patients a chance of cure. These patients, Mark and M.F., I will ask you guys to comment. The number one thing I have learned from my KOLs here, they are asking to be off therapy for life. They want cure. Mark, M.F., any comments on that?
Well, I can certainly jump in. I think the phase II, if we go back to that, it is a really elegant design. What I mean by that is you have got a monotherapy arm that is going to attack cccDNA and providing one pathway to NUC-free, no medication for patients living with hepatitis B. The second arm, which does PBGENE to cut the ccc, followed by bepirovirsen, really provides an additional pathway forward, both for the potential for higher rates of viral cure, but also to remove that integrated S-antigen through bepirovirsen's effect, primarily through the immune system as well as through its ASO function. Really, two shots, if you will, to take a patient with chronic hepatitis B on long-term NUCs to a cure state in which antiviral therapy in the form of daily NUCs is not needed.
Maybe I can supplement that, my daily practice from what patients really want. Because number one, patients who saw us, if we decided to ask them or ask her to start antiviral, the first one, because they know that, "Should I need to take it long term or lifelong even?" This is a quick, I mean, I would say obstacle for patients to consider to take on the therapy. That is why, I mean, when I started this particular trial, you can see that we actually recruited quite a lot in a single center, the first gene therapy. The reason is very simple. The patients really want to take off therapy.
That is why this is a great need, and we love to see the results, and we are hopeful that this therapy can actually take off a lot of patients from nucleoside analogs where they really don't want to take for life.
Thank you, M.F. Thanks so much. Operator, next questions, please.
Yes, the next question comes from Catherine Novack at JonesTrading.
Hi, Catherine.
Hi. Good morning. Thanks for taking my question.
Of course.
My first question is for Dr. Sulkowski and Dr. Yuen. Can you discuss long-term outcome difference in patients, whether they achieve functional or viral cure? Let's say viral cure looks similar to functional cure rates in phase II, how do you think about choosing one or the other? From an access standpoint, do you think payers are willing to attempt multiple curative regimens for HBV patients?
Yeah, Mark, I've seen you do a lot on this. I would love to. Obviously, the viral cure rate is zero, Catherine. Mark, I'd love for you to talk about the context of functional cure and a bit of a fragile endpoint and what's happening with HCC rates today, and your thought of some of the differences with viral, please. M.F., feel free to chime in.
Yeah, let me jump into that. The biggest threat to people with hepatitis B is the potential for hepatocellular carcinoma. If we look at studies of both natural history of hepatitis B, that is treatment without NUCs and then treatment with NUCs, you see that the biomarker of DNA is a strong predictor of future risk. Viral replication drives, if you will, cancer risk in the future, and NUCs suppress it, but it's incomplete. When you look at other biomarkers, S-antigen is a biomarker as well, but both biomarkers in the blood have depicted the higher they are, the greater the risk of cancer over time. Of course, M.F. has done a lot of that work, so I'm going to turn it over to M.F. to talk further about the studies that he's conducted in Hong Kong.
Thank you very much, Mark. In fact, this is a very practical question. We know that patients who achieve functional cure, they are expected to have a lower risk, significantly lower risk of developing liver cancer and cirrhosis, and that obviously will improve the outcome for the patients. Even patients who cannot achieve loss of surface antigen, if we somehow can lower the surface antigen, it has been shown scientifically with strong evidence that patients who have relatively low surface antigen level, then the outcome is still better than patients who are having high surface antigen. We have shown in this particular study, these patients, although at this stage, we don't see surface antigen loss in these particular studies, we know that these patients have at least, on average, 40%-50% reduction of the surface antigen, and which is sustained in this particular study.
We know that, okay, these patients is now having a lower risk of HCC, and we really want to strive better to have a viral control to take off the patient from nucleoside analogs, to have a functional cure to take off patient from nucleoside analogs. These are the things that we really hoping for, and that I think we'll have a high chance of getting there with PBGENE therapy.
Yeah, Catherine, to be fair, there's some different global regions here. I'll take the payer question. First of all, it's early. It's incredibly exciting that it's phase I, and we're showing really an elimination of a virus that will compare to suppression, and what that really means over time for late-stage liver outcomes. Look, Catherine, we know the greatest influx. There's a lot of thin data of what happens if an integrant sticks around for years and years and years. Does S or X lead to deleterious go-forward condition, cancer risk? Data's thin at best. We do know the following, that when a patient is in their early infected state, like that E positive patient, and that fire hose is on of replicating virus, which is where the fragments go into the integrated host genome.
We know that number of frequencies, place you get those integrations, near or not near an oncogene, leads to cancer risks. We know that shutting down viral replication, we think is going to have a profound impact on late-stage liver disease. The payers accordingly, look, the payers today are paying very Look, we've had a 3% functional cure rate for 50 years. Great step forward with bepirovirsen. We're excited for patients. Now we're at 19%. We still got 81% of patients that we can't leave behind, but bepirovirsen's being reimbursed well on a suppression endpoint of functional cure. I think an elimination or an extinguish of the actual DNA source of replicating virus, and what that could mean for late-stage liver disease outcomes, which are still not going down fast enough, that's for sure. Depends what data you look at.
Some show rates going up and not going down fast enough. There'll always be a value-based medicine decision to be made, and I think payers are going to have shown they'll support that for patients. Very early phase I to talk a bit about payers, but I don't think you should worry about a viral cure, true elimination versus a functional cure. We know that functional cure is beneficial for patients and reimbursed today.
Great. Thanks, M.F. I guess just one more for the Precision team. Just speak, I guess, to the relative ability of PBGENE-HBV to target integrated viral DNA versus cccDNA. How is that borne out in patients versus what you see pre-clinically?
Yeah, I'm going to ask Cassie to jump in and really take you through that. Remember, PBGENE-HBV is the cccDNA drug. We knock down, but we don't eliminate integrations, and we're okay with that. We don't think integrations have any deleterious go-forward effect anywhere near the world of what the actual source of DNA is. The liver will turn over, we know that, and it gets rid of those fragments that are integrated. Remember, Catherine, they cannot make viral replication competent disease. Cassie, can you weigh in a little bit and maybe tie that to our mechanism?
Sure. What we've seen pre-clinically and now is supported in the clinical biopsy data is that when that ARCUS nuclease cuts cccDNA, the predominant outcome is the elimination of that cccDNA molecule. The double strand break leads to degradation, loss of that cccDNA. Obviously, when you eliminate cccDNA, you eliminate anything that was previously being produced from that molecule. Any of the viral antigens, pgRNA, S-antigen, all goes with it when you eliminate cccDNA. There's a secondary mechanism that can occur in both cccDNA as well as integrated DNA, and that's indels, insertions of single base nucleotides into that DNA sequence. We know that those indels inactivate cccDNA because of where the target site sits in the cccDNA. They also render cccDNA replication incompetent. There's two editing outcomes on cccDNA.
Elimination happens 90% of the time, and then the indel outcome, which is the minority outcome, still effective for replication incompetency. On integrated DNA, the editing outcome indels, we can see that that happens in the liver biopsy data. However, what we know, as Michael said, that editing of integrated DNA reduces S-antigen, but doesn't completely shut off S-antigen expression from integrants, which is why we see reductions, stable decline in S-antigen in our patients.
Thank you very much.
Thank you for the questions, Catherine. The next question comes from Kostas Biliouris at Oppenheimer.
Thanks for taking our questions, and congrats on the multiple great updates here. Two questions from us on HBV and one on DMD, because I hope it is not overlooked today, DMD. On HBV, the first question is, there is a patient who was treated with a fourth dose about 35 months after the third dose. I wonder what was the decision behind the timing of the fourth dose, and all this while the patient was pgRNA negative. Second question, on the mice data, you showed what happens when we have ASO treatment only and when we have combo of gene editing and ASO. I wonder what happens when you dose the mice with only gene editing. Do you have this data and what—
Yeah.
—does it look like?
Yeah. So, of course. I will have Cassie address that in a minute, and Cassie, you will have to explain that. Kostas, that is arm one of the trial. If you have viral cure, there is no reason for a combo. That is correct. If you have 100% viral cure rate, there will be no reason for a bepirovirsen combo. If the truth is somewhere between 0% and 100% on a viral cure, which is probably where we will be, that is where the combo could help some patients. I will ask Cassie to touch that.
Let me first talk about one of M.F.'s patients, and I will let him weigh in in a moment. We are getting on time. Remember, we dosed one patient four times at 0.4. That was in the early days, cohort two, true phase I dose finding. We did not know 0.4, Kostas, would be the dose yet. It was actually M.F.'s patient.
I'll have him weigh in in a minute, but he is my lead PI and investigator, and one of the things M.F. and I wanted to answer was safety. Safety. We didn't know that everyone was going to go pgRNA undetectable at two admins. If you look at that swimmer's plot close, be careful, folks, when you do, because it looks like, for example, patient six goes undetectable at that third diamond. But really, that's the blood biomarker draw before you dose them. No one has ever needed more than two admins, Kostas. We'll give three in our study to be safe and make sure we got all the disease.
But M.F. and I at the time were saying, "What does fourth admin look like for safety, if we ever need to give a fourth admin, if there is somebody who's still pgRNA detectable?" We also had a patient who still had some S-antigen. So even though we treated beyond the biomarker, to be fair, M.F., at the time, we didn't know pgRNA was definitely our holy grail only biomarker, so we treated beyond the biomarker. I don't think we saw an additional benefit on the integrated S, because we've eliminated the cccDNA S. And really important, M.F. does an incredible job, and his patient was willing to give us a biopsy on another treatment, and that really factored into our decision too. Of course, safety for the patient, but really moving science forward for all patients. M.F., how did I do on that patient six?
Did I miss any of our rationale behind it? Let me know.
You mentioned, I mean, completely correct. That particular patient is very motivated. When I talked to him, actually, whether he wants to try another dose, he said yes, because, I mean, we understand this is a very early phase study. I mean, at this stage, we are looking something from hindsight, right? So we have the pgRNA ready for these patients. We know the surface antigen. Now, I mean, we know that with all this data, we are now settling in three doses in the phase III. But the important for that particular patient is even we didn't see any pregenomic RNA level in the blood. We didn't see the surface antigen further drop by the fourth dose, but we see an additional 1.5 log reduction of the cccDNA. So we are now balancing the number of doses versus the effect on the patient.
We come up with the conclusion of using three doses in the phase II study.
Thank you, M.F. Cassie, on the combo question in the mouse data, I think this is profound that you almost have to, Cassie, hit from the standpoint that if you eradicate all cccDNA, you won't have a transgenic mouse model that works, but maybe go from there, Cassie, on why you have to leave some targets, if you will, by underdosing the PBGENE-HBV in the mouse. Go ahead.
Yeah, great question, Kostas. In that transgenic mouse model, actually done two different dose levels of PBGENE-HBV and HBV. At a higher dose level of PBGENE-HBV and HBV, we can eliminate the detectable pgRNA. We have sustained S-antigen reduction, and in that model, we've previously shared this data, actually a couple years ago. It's not this data. Sorry, I don't want to get confused.
That's okay. But you can leave this slide on. We don't have the other data she's talking about on the deck. Go ahead, Cassie.
In this same mouse model, we have given a sufficient dose of PBGENE-HBV to drive undetectable HBV DNA off NUCs. We have demonstrated by proof of principle that you can achieve that viral cure endpoint in this transgenic mouse at a sufficient PBGENE-HBV dose. Now, in this study, whenever we wanted to look for synergy with bepirovirsen, we dosed at a lower dose level of PBGENE-HBV because we knew that we could get that viral cure. To Michael's point, if you're achieving 100% viral cure, you don't need a combination. The point here is to look for synergy, so you dose at a lower dose level so that the two can demonstrate added benefit. In this particular dose, this was a 0.1 mg/kg single dose of PBGENE-HBV prior to the finite course of the ASO here.
Hopefully that clarifies your question. We can see viral cure in this mouse model with an appropriate PBGENE-HBV dose, and with a lower dose level, we can see synergy between the two.
Kostas.
Thank you.
You really have to stack the deck against yourself here to do the design. If there is a worst-case scenario and any pgRNA via cccDNA is left behind, you now see through this model, 1+1 could equal not three, hopefully 27. That is the idea. But the goal here is that you would eradicate, to your point, Kostas, in many, many patients, and this would be a moot point.
Thank you. Maybe one on DMD.
Yes, go ahead. We love DMD. We appreciate you saying, "Don't forget about our other child." We love that update too. Thanks, Kostas. Go ahead.
Exactly. I am not sure you love both children the same, but my question is the following. In ELEVIDYS and REGENXBIO data, we saw that at 12 weeks, the percentage of microdystrophin varies across different ages. Obviously, different approaches across the board, but I was wondering how old is the patient that you have dosed, whether you can disclose that, and how old are the other patients that you are planning to dose with this first dose? Thank you.
Kostas, I am going to go to the DMD expert here in a moment, and that is Cassie, and really my boss most days. I am not going to let the conversation go until I make one critical point up front. We are rooting for patients, so we are never rooting against any therapies out there. God knows DMD, there is great room for improvement needed. I want to be careful when you compare a synthetic dystrophin that we know has lit up biomarkers, but unfortunately has not translated to the functional improvements we need, versus, and I will have Cassie weigh in in a minute here, you even look at the Dyne data, 2.5% of something real, true body native dystrophin really made a meaningful impact.
Cassie, can we talk a little bit about the three-month mark- maybe what you should and should not expect from function due to steroids, and just make sure we are talking about what we are measuring near full length, please, Cassie.
Yeah, sure. Thank you. Thank you for the question, Kostas. First off, I will take your question about the age range we are enrolling. We have not given particulars on the exact age of the first participant dosed in the study, but I will draw your attention to two- to seven-year-olds as the inclusion criteria here, and that is consistent with what we see across many of the microdystrophin studies. I want to draw out an important difference. One is that the four- to seven-year-olds, I will say, that is typically when you start to get diagnosed with DMD, you start to see functional decline is around that four to five age, and many kids are diagnosed at that point. We think that is an important population for our study because correlating the dystrophin expression with functional benefits is more straightforward in that population.
There has been more historical experience in DMD studies around that age range. However, for a gene editing approach, which ours obviously is, that younger population is really important. If you think about it, if you could intervene into that disease course earlier and prevent muscle loss over time early in those two- to four-year-olds, that could be really meaningful for longer term outcomes. It may come with some challenges on measuring the functional benefit, but we have incorporated some novel endpoints, like the Sysnav wearable devices to look at across that age range, the ability for PBGENE-HBV to impact function. We are very confident with the age range we are enrolling. We do think that there is benefit in going in younger, but we know that many of these kids are diagnosed and start to show decline in that four- to five-year age range.
I think it's a comprehensive approach to treat this population. That's kind of the rationale for how we've thought about it. Now, as we think about the muscle biopsy data, obviously three months is our first look at dystrophin protein expression. These kids do go on steroids as part of the dosing premedication regimen, either steroids for the first time or an increased dose of steroids if they've previously been on steroids. That may impact the ability to interpret the functional data, the early functional data. I think we will look at the later biopsy data, the 12-month biopsy data, the ability to correlate that dystrophin protein expression with functional benefit at that timeframe, and that will be really important as we think about what's next. Three-month biopsy data, but of course, 12-month biopsy data and functional benefit.
Thank you, Kostas.
Thank you.
Thank you, Cassie. Of course, that's PBGENE-DMD. That being said, we're really excited about that program. Kostas, I appreciate you calling me on it. We do love both of our children. Of course, we're looking at a bigger dataset coming off of yesterday, M.F.'s presentation. I want to do a few things here as we close up. I want to thank our patients globally. Without them, there is no data to possibly move this field forward in both disease states. I want to thank the leadership of our principal investigator, M.F. Yuen. I want to thank Mark Sulkowski, who's been working with the team for the last two years and really took Precision to an expert level here in the infectious disease therapeutic area. I want to thank our investors.
I want to thank our partners who have been with us, who were willing with us to get to the next late-stage inflection point. I want to welcome and thank our new partners who have come in. We are really excited about that. We think we have a group of really great fundamental investors who want to see good things happen through data for patients, and those are the kind of partners we want to do high science, high integrity science here at Precision BioSciences. I want to thank my team for the execution and all of your attention today. Thank you to our sell-side analysts, and we wish everybody well. We will talk again soon. Thank you.
This concludes today's call. You may disconnect your line.